NEW YORK (GenomeWeb) – Contextual Genomics has signed a deal to offer its Find-It solid tumor test in Brazil through Sao Paulo-based diagnostics firm Idengene, the companies said today.
Find-It is a next-generation sequencing-based multiplex assay that screens 120 hotspots and 17 exons in 33 known cancer genes to help clinicians select the best treatment for a specific patient, recognize acquired drug-resistant mutations, and determine prognostic and diagnostic implications for patient care.
Under the terms of the deal, Idengene will offer Find-It through its laboratory to its network of cancer clinical practice sites in Brazil. It will also have access to Contextual's quality control systems, treatment indications database, and physician report generation system.
Additional terms were not disclosed.
"Idengene's presence in Brazil will broaden access to quality DNA-based diagnostics and can lead to better outcomes for patients diagnosed with cancer," Contextual Genomics CSO Samuel Aparicio said in a statement.
Earlier this year, Australia's Sonic Healthcare began offering Find-It through its international network of laboratories.